Evicenter
P&T meetings

Tirabrutinib

Primary central nervous system lymphoma

Regulatory submission
NDA submitted December 2025
Last updated
72 sources

Product information and disease descriptionProduct descriptionProduct informationPharmacology

Pharmacokinetics

2 evidence topics · 2 sources

Pharmacokinetics: healthy subjects and rheumatoid arthritis

“A biphasic PK profile was shown with median half-life ranging from ~ 6.2 to ~ 7.3 hours.” (opens the source at this quote in a new tab)

Metabolism

“The primary metabolic enzyme of tirabrutinib was CYP3A4 (in vitro).” (opens the source at this quote in a new tab)